These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 32487558

  • 21. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
    Chebib FT, Torres VE.
    Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
    [Abstract] [Full Text] [Related]

  • 22. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.
    PLoS One; 2017 Aug; 12(3):e0174583. PubMed ID: 28346513
    [Abstract] [Full Text] [Related]

  • 23. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the KoreaN cohort study for outcomes in patients with chronic kidney disease.
    Kim H, Koh J, Park SK, Oh KH, Kim YH, Kim Y, Ahn C, Oh YK.
    Nephrology (Carlton); 2019 Apr; 24(4):422-429. PubMed ID: 29797773
    [Abstract] [Full Text] [Related]

  • 24. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW, HALT-PKD Study.
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D, the HALT Investigators.
    Am J Nephrol; 2020 Feb; 51(6):473-479. PubMed ID: 32541154
    [Abstract] [Full Text] [Related]

  • 30. Automated prognosis of renal function decline in ADPKD patients using deep learning.
    Raj A, Tollens F, Caroli A, Nörenberg D, Zöllner FG.
    Z Med Phys; 2024 May; 34(2):330-342. PubMed ID: 37612178
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
    Blijdorp CJ, Severs D, Musterd-Bhaggoe UM, Gansevoort RT, Zietse R, Hoorn EJ, DIPAK Consortium.
    Nephrol Dial Transplant; 2021 Dec 02; 36(12):2248-2255. PubMed ID: 33377160
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.
    Am J Nephrol; 2016 Dec 02; 44(3):171-8. PubMed ID: 27548646
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
    Horie S.
    Kidney Int; 2015 Jul 02; 88(1):14-6. PubMed ID: 26126090
    [Abstract] [Full Text] [Related]

  • 37. Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients.
    Sans L, Pascual J, Radosevic A, Quintian C, Ble M, Molina L, Mojal S, Ballarin JA, Torra R, Fernández-Llama P.
    Medicine (Baltimore); 2016 Dec 02; 95(49):e5595. PubMed ID: 27930582
    [Abstract] [Full Text] [Related]

  • 38. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Knebelmann B, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Antonshchuk I, Perrone RD.
    Am J Kidney Dis; 2023 May 02; 81(5):517-527.e1. PubMed ID: 36535535
    [Abstract] [Full Text] [Related]

  • 39. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
    Knol MGE, Bais T, Geertsema P, Connelly MA, Bakker SJL, Gansevoort RT, van Gastel MDA, DIPAK Consortium .
    Nephrol Dial Transplant; 2024 Apr 26; 39(5):838-847. PubMed ID: 37974030
    [Abstract] [Full Text] [Related]

  • 40. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.